Franco M Buonaguro

List of Publications by Year
in descending order

230	8,596	44444	68831
papers	citations	50 h-index	81 g-index

241	241	241	13730
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Virus-like Particles as Preventive and Therapeutic Cancer Vaccines. Vaccines, 2022, 10, 227.	2.1	36
2	Neoantigens as potential vaccines in hepatocellular carcinoma. , 2022, 10, e003978.		16
3	Mutations in the telomerase reverse transcriptase promoter and PIK3CA gene are common events in penile squamous cell carcinoma of Italian and Ugandan patients. International Journal of Cancer, 2022, 150, 1879-1888.	2.3	5
4	Novel Molecular Targets for Hepatocellular Carcinoma. Cancers, 2022, 14, 140.	1.7	8
5	Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma. Clinical Cancer Research, 2022, 28, 2555-2566.	3.2	31
6	An overview of â€œChronic viral infection and cancer, openings for vaccinesâ€•virtual symposium of the TechVac NetworkÂ-ÂDecember 16-17, 2021. Infectious Agents and Cancer, 2022, 17, .	1.2	0
7	Pathogens: Our Allies against Cancer?. Molecular Therapy, 2021, 29, 10-12.	3.7	9
8	PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virusâ€•related diseases. Liver International, 2021, 41, 133-149.	1.9	3
9	Identification and characterization of heteroclitic peptides in TCR-binding positions with improved HLA-binding efficacy. Journal of Translational Medicine, 2021, 19, 89.	1.8	8
10	The Role of circRNAs in Human Papillomavirus (HPV)-Associated Cancers. Cancers, 2021, 13, 1173.	1.7	11
11	Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs).. , 2021, 9, e002694.		19
12	Clinical Significance of Telomerase Reverse-Transcriptase Promoter Mutations in Hepatocellular Carcinoma. Cancers, 2021, 13, 3771.	1.7	7
13	MHC-Optimized Peptide Scaffold for Improved Antigen Presentation and Anti-Tumor Response. Frontiers in Immunology, 2021, 12, 769799.	2.2	6
14	Profiling the HCV immune response in patients with chronic liver diseases and hepatocellular carcinoma by peptide microarray analysis. Current Medicinal Chemistry, 2021, 28, .	1.2	1
15	Long-term memory T cells as preventive anticancer immunity elicited by TuA-derived heteroclitic peptides. Journal of Translational Medicine, 2021, 19, 526.	1.8	3
16	Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches. Cancer Letters, 2020, 473, 25-32.	3.2	40
17	Modeling the epithelial-mesenchymal transition process in a 3D organotypic cervical neoplasia. Acta Biomaterialia, 2020, 116, 209-222.	4.1	11
18	The clinical and translational research activities at the INT â€“ IRCCS â€œFondazione Pascaleâ€•cancer center (Naples, Italy) during the COVID-19 pandemic. Infectious Agents and Cancer, 2020, 15, 69.	1.2	8

#	Article	IF	Citations
19	Detection of Human Papillomaviruses in the Nasopharynx of Breastfed Infants: New Findings and Meta-Analysis. Viruses, 2020, 12, 1119.	1.5	10
20	Global and regional epidemiology of HIV-1 recombinants in 1990â€“2015: a systematic review and global survey. Lancet HIV,the, 2020, 7, e772-e781.	2.1	51
21	Selecting Target Antigens for Cancer Vaccine Development. Vaccines, 2020, 8, 615.	2.1	59
22	Human Papillomavirus and Cancers. Cancers, 2020, 12, 3772.	1.7	6
23	High somatic mutation and neoantigen burden do not correlate with decreased progression-free survival in HCC patients. Journal of Hepatology, 2020, 73, S566.	1.8	0
24	Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment. Infectious Agents and Cancer, 2020, 15, 32.	1.2	10
25	SARS-CoV-2 RNA polymerase as target for antiviral therapy. Journal of Translational Medicine, 2020, 18, 185.	1.8	64
26	The Role of RNA Splicing Factors in Cancer: Regulation of Viral and Human Gene Expression in Human Papillomavirus-Related Cervical Cancer. Frontiers in Cell and Developmental Biology, 2020, 8, 474.	1.8	43
27	Antimicrobial Peptides as Anticancer Agents: Functional Properties and Biological Activities. Molecules, 2020, 25, 2850.	1.7	204
28	Detection of a large spectrum of viral infections in conjunctival premalignant and malignant lesions. International Journal of Cancer, 2020, 147, 2862-2870.	2.3	8
29	Covidâ€19: Time for a paradigm change. Reviews in Medical Virology, 2020, 30, e2134.	3.9	47
30	The Role of microRNAs, Long Non-coding RNAs, and Circular RNAs in Cervical Cancer. Frontiers in Oncology, 2020, 10, 150.	1.3	146
31	Immunological effects of adjuvants in subsets of antigen presenting cells of cancer patients undergoing chemotherapy. Journal of Translational Medicine, 2020, 18, 34.	1.8	10
32	Nanoparticles to Improve the Efficacy of Peptide-Based Cancer Vaccines. Cancers, 2020, 12, 1049.	1.7	51
33	Anti-IL6R role in treatment of COVID-19-related ARDS. Journal of Translational Medicine, 2020, 18, 165.	1.8	82
34	Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma. Genome Medicine, 2019, 11, 28.	3.6	107
35	Immunotherapy in hepatocellular carcinoma. Annals of Hepatology, 2019, 18, 291-297.	0.6	66
36	Uncovering â€œhiddenâ€•mutations in hepatocellular carcinoma: the use of droplet digital PCR to detect TERT promoter mutations. Digestive and Liver Disease, 2019, 51, e37.	0.4	0

#	Article	IF	Citations
37	Cancer Diagnostic and Predictive Biomarkers 2018. BioMed Research International, 2019, 2019, 1-3.	0.9	3
38	Clinical Significance of Polymorphisms in Immune Response Genes in Hepatitis C-Related Hepatocellular Carcinoma. Frontiers in Microbiology, 2019, 10, 475.	1.5	11
39	High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy. Cancers, 2019, 11, 1824.	1.7	36
40	Global and regional molecular epidemiology of HIV-1, 1990â€“2015: a systematic review, global survey, and trend analysis. Lancet Infectious Diseases, The, 2019, 19, 143-155.	4.6	255
41	Precision medicine in gastric cancer. World Journal of Gastrointestinal Oncology, 2019, 11, 804-829.	0.8	56
42	Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma. International Journal of Cancer, 2018, 143, 1153-1161.	2.3	30
43	Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches. Redox Biology, 2018, 15, 467-479.	3.9	196
44	Cellular prognostic markers in hepatitis-related hepatocellular carcinoma. Infectious Agents and Cancer, 2018, 13, 10.	1.2	18
45	P-G5 Differential immune response to HCV peptides as cancer-progression biomarkers of HCV-infections. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 63-63.	0.9	0
46	Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients. Journal of Translational Medicine, 2018, 16, 286.	1.8	24
47	Prevalence of â€œunclassifiedâ€•HPV genotypes among women with abnormal cytology. Infectious Agents and Cancer, 2018, 13, 26.	1.2	10
48	Potentiating cancer vaccine efficacy in liver cancer. OncoImmunology, 2018, 7, e1488564.	2.1	26
49	Human Oncoviruses and p53 Tumor Suppressor Pathway Deregulation at the Origin of Human Cancers. Cancers, 2018, 10, 213.	1.7	61
50	The Role of Circulating Free DNA and MicroRNA in Non-Invasive Diagnosis of HBV- and HCV-Related Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2018, 19, 1007.	1.8	50
51	Cell Penetrating Peptides as Molecular Carriers for Anti-Cancer Agents. Molecules, 2018, 23, 295.	1.7	204
52	Telomerase promoter mutations in human immunodeficiency virus-related conjunctiva neoplasia. Journal of Translational Medicine, 2018, 16, 77.	1.8	8
53	Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting. Oncotarget, 2018, 9, 3576-3589.	0.8	19
54	The Role of Sensing Peptides in the Cross-talk between Microbiota and Human Cancer Cells. Mini-Reviews in Medicinal Chemistry, 2018, 18, 1567-1571.	1.1	4

#	Article	IF	Citations
55	MDM2 gene polymorphisms and risk of classic Kaposiâ€™s sarcoma among Iranian patients. Medical Microbiology and Immunology, 2017, 206, 157-163.	2.6	3
56	Use of adjuvants for immunotherapy. Human Vaccines and Immunotherapeutics, 2017, 13, 1774-1777.	1.4	27
57	TERT promoter and CTNNB1 gene mutations represent cancer signatures specific for hepatitis B and hepatitis C related hepatocellular carcinoma. Digestive and Liver Disease, 2017, 49, e27.	0.4	0
58	An Engineered Cellâ€Instructive Stroma for the Fabrication of a Novel Full Thickness Human Cervix Equivalent In Vitro. Advanced Healthcare Materials, 2017, 6, 1601199.	3.9	24
59	Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinoma. Infectious Agents and Cancer, 2017, 12, 27.	1.2	40
60	Effect of electrochemotherapy on human herpesvirus 8 kinetics in classic Kaposi sarcoma. Infectious Agents and Cancer, 2017, 12, 35.	1.2	8
61	New vaccination strategies in liver cancer. Cytokine and Growth Factor Reviews, 2017, 36, 125-129.	3.2	20
62	Immunological effects of a novel RNA-based adjuvant in liver cancer patients. Cancer Immunology, Immunotherapy, 2017, 66, 103-112.	2.0	23
63	Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference. Preventive Medicine, 2017, 98, 21-30.	1.6	49
64	New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology. Molecules, 2017, 22, 1282.	1.7	54
65	Cancer Diagnostic and Predictive Biomarkers 2016. BioMed Research International, 2017, 2017, 1-2.	0.9	9
66	Vaccine Approaches in Hepatocellular Carcinoma. , 2017, , 1-17.		1
67	Comparative analysis of HPV16 gene expression profiles in cervical and in oropharyngeal squamous cell carcinoma. Oncotarget, 2017, 8, 34070-34081.	0.8	21
68	An Overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases. Mini-Reviews in Medicinal Chemistry, 2017, 17, 758-770.	1.1	19
69	Solid Phase Formylation of N-Terminus Peptides. Molecules, 2016, 21, 736.	1.7	8
70	A-108â€ƒViral and cellular biomarkers in HPV-related cancers. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 37.	0.9	0
71	Application of the Immunoscore as prognostic tool for hepatocellular carcinoma. , 2016, 4, 71.		12
72	What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO). , 2016, 4, .		0

#	Article	IF	Citations
73	Detection of human papillomavirus DNA in peri-tumor tissues and pelvic lymph nodes as potential molecular marker of micrometastasis in cervical cancer. Infectious Agents and Cancer, 2016, 11, 22.	1.2	7
74	Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery. Scientific Reports, 2016, 6, 29258.	1.6	22
75	Infectious Agents and Cancer reviewer acknowledgement 2015. Infectious Agents and Cancer, 2016, 11, .	1.2	0
76	Cancer vaccines for hepatocellular carcinoma: future directions. Immunotherapy, 2016, 8, 391-393.	1.0	3
77	Combinatorial immunotherapy strategies for hepatocellular carcinoma. Current Opinion in Immunology, 2016, 39, 103-113.	2.4	52
78	A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice. Journal of Translational Medicine, 2016, 14, 58.	1.8	18
79	Developments in cancer vaccines for hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2016, 65, 93-99.	2.0	55
80	Abstract A044: Immunological effects of a novel RNA-based adjuvant in liver cancer patients. , 2016, , .		1
81	Candidate Soluble Immune Mediators in Young Women with High-Risk Human Papillomavirus Infection: High Expression of Chemokines Promoting Angiogenesis and Cell Proliferation. PLoS ONE, 2016, 11, e0151851.	1.1	17
82	Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget, 2016, 7, 25087-25102.	0.8	60
83	HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2. Oncotarget, 2016, 7, 37487-37497.	0.8	16
84	Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma. Oncotarget, 2016, 7, 54253-54262.	0.8	50
85	Abstract B130: Evaluation of novel metronomic chemotherapy and cancer vaccine combinatorial strategy. , 2016, , .		0
86	Abstract 742: A novel multidrug metronomic chemotherapy significantly delays tumor growth in mice. , 2016, , .		0
87	Abstract A045: Inhibition of tumor growth by combination of metronomic chemotherapy and checkpoint inhibitor with a cancer vaccine. , 2016, , .		0
88	Abstract A046: Identification and validation of HCC-specific gene transcriptional signature for tumor antigen discovery. , 2016, , .		0
89	Impairment of T cell development and acute inflammatory response in HIV-1 Tat transgenic mice. Scientific Reports, 2015, 5, 13864.	1.6	31
90	Functional characterization of biodegradable nanoparticles as antigen delivery system. Journal of Experimental and Clinical Cancer Research, 2015, 34, 114.	3.5	24

#	Article	IF	Citations
91	Identification of Human Herpesvirus 8 Sequences in Conjunctiva Intraepithelial Neoplasia and Squamous Cell Carcinoma of Ugandan Patients. BioMed Research International, 2015, 2015, 1-7.	0.9	9
92	Cancer Diagnostic and Predictive Biomarkers 2015. BioMed Research International, 2015, 2015, 1-1.	0.9	0
93	Systems Biology Approach for Cancer Vaccine Development and Evaluation. Vaccines, 2015, 3, 544-555.	2.1	10
94	Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model. Cancer Immunology, Immunotherapy, 2015, 64, 1305-1314.	2.0	31
95	Cellular prognostic markers in hepatocellular carcinoma. Future Oncology, 2015, 11, 1591-1598.	1.1	20
96	An overview of new biomolecular pathways in pathogen-related cancers. Future Oncology, 2015, 11, 1625-1639.	1.1	12
97	Cancer biomarkers. Future Oncology, 2015, 11, 1585-1586.	1.1	0
98	The XIX century smallpox prevention in Naples and the risk of transmission of human blood-related pathogens. Journal of Translational Medicine, 2015, 13, 33.	1.8	7
99	Update on Head and Neck Cancer: Current Knowledge on Epidemiology, Risk Factors, Molecular Features and Novel Therapies. Oncology, 2015, 89, 125-136.	0.9	143
100	Genetic Diversity of the KIR/HLA System and Susceptibility to Hepatitis C Virus-Related Diseases. PLoS ONE, 2015, 10, e0117420.	1.1	54
101	Formation of self-assembled triple-layered rotavirus-like particles (tlRLPs) by constitutive co-expression of VP2, VP6, and VP7 in stably transfected high-five insect cell lines. Journal of Medical Virology, 2015, 87, 102-111.	2.5	15
102	Cancer Diagnostic and Predictive Biomarkers. BioMed Research International, 2014, 2014, 1-3.	0.9	12
103	CDK/CCN and CDKI Alterations for Cancer Prognosis and Therapeutic Predictivity. BioMed Research International, 2014, 2014, 1-15.	0.9	60
104	The Functional Role of MnSOD as a Biomarker of Human Diseases and Therapeutic Potential of a New Isoform of a Human Recombinant MnSOD. BioMed Research International, 2014, 2014, 1-11.	0.9	33
105	Antigen-specific vaccines for cancer treatment. Human Vaccines and Immunotherapeutics, 2014, 10, 3332-3346.	1.4	124
106	TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix. Journal of Translational Medicine, 2014, 12, 255.	1.8	51
107	Impact of Immunogenetic IL28B Polymorphism on Natural Outcome of HCV Infection. BioMed Research International, 2014, 2014, 1-8.	0.9	16
108	Aberrant Glycosylation as Biomarker for Cancer: Focus on CD43. BioMed Research International, 2014, 2014, 1-13.	0.9	100

#	Article	IF	Citations
109	Burkitt lymphoma research in East Africa: highlights from the 9th African organization for research and training in cancer conference held in Durban, South Africa in 2013. Infectious Agents and Cancer, 2014, 9, 32.	1.2	8
110	Cancer-Associated CD43 Glycoforms as Target of Immunotherapy. Molecular Cancer Therapeutics, 2014, 13, 752-762.	1.9	32
111	Human Papillomavirus Infection and Cervical Neoplasia among Migrant Women Living in Italy. Frontiers in Oncology, 2014, 4, 31.	1.3	20
112	Corrigendum to: â€œChallenges in cancer vaccine development for hepatocellular carcinomaâ€•[J Hepatol 2013;59:897â€“903]. Journal of Hepatology, 2014, 60, 237.	1.8	0
113	Prediction of individual immune responsiveness to a candidate vaccine by a systems vaccinology approach. Journal of Translational Medicine, 2014, 12, 11.	1.8	8
114	Systems vaccinology for cancer vaccine development. Expert Review of Vaccines, 2014, 13, 711-719.	2.0	2
115	HPV-related oropharyngeal cancers: From pathogenesis to new therapeutic approaches. Cancer Letters, 2014, 351, 198-205.	3.2	37
116	Pattern of activation of human antigen presenting cells by genotype GII.4 norovirus virus-like particles. Journal of Translational Medicine, 2013, 11, 127.	1.8	12
117	Infections and cancer: debate about using vaccines as a cancer control tool. Infectious Agents and Cancer, 2013, 8, 16.	1.2	5
118	Infectious Agents & Cancer reviewer acknowledgement 2012. Infectious Agents and Cancer, 2013, 8, .	1.2	0
119	Somatic mutations of STK11 gene in human papillomavirus positive and negative penile cancer. Infectious Agents and Cancer, 2013, 8, 2.	1.2	9
120	Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: A systematic review. Gynecologic Oncology, 2013, 128, 442-448.	0.6	54
121	New developments in cancer vaccines. Expert Review of Vaccines, 2013, 12, 1109-1110.	2.0	5
122	Clinical oncology in resource-limited settings. Infectious Agents and Cancer, 2013, 8, 39.	1.2	5
123	Kaposiâ€™s sarcoma: Etiology and pathogenesis, inducing factors, causal associations, and treatments: Facts and controversies. Clinics in Dermatology, 2013, 31, 413-422.	0.8	93
124	Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate. Journal of Translational Medicine, 2013, 11, 165.	1.8	9
125	Challenges in cancer vaccine development for hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 897-903.	1.8	87
126	Identification and sequence analysis of a novel human leukocyte antigen allele B*51:141. Tissue Antigens, 2013, 81, 55-56.	1.0	3

#	Article	IF	Citations
127	Development of a stable insect cell line constitutively expressing rotavirus VP2. Virus Research, 2013, 172, 66-74.	1.1	8
128	The application of virus-like particles to human diseases. Expert Review of Vaccines, 2013, 12, 99-99.	2.0	6
129	Developments in virus-like particle-based vaccines for HIV. Expert Review of Vaccines, 2013, 12, 119-127.	2.0	14
130	Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Genomics, 2013, 102, 74-83.	1.3	140
131	Molecular Signatures Associated with HCV-Induced Hepatocellular Carcinoma and Liver Metastasis. PLoS ONE, 2013, 8, e56153.	1.1	22
132	Viral and Cellular Biomarkers in the Diagnosis of Cervical Intraepithelial Neoplasia and Cancer. BioMed Research International, 2013, 2013, 1-10.	0.9	96
133	VLPs and particle strategies for cancer vaccines. Expert Review of Vaccines, 2013, 12, 1173-1193.	2.0	17
134	Selected HIV-1 Env Trimeric Formulations Act as Potent Immunogens in a Rabbit Vaccination Model. PLoS ONE, 2013, 8, e74552.	1.1	12
135	Chemokine Receptor Interactions with Virus-Like Particles. Methods in Molecular Biology, 2013, 1013, 57-66.	0.4	2
136	AIDS AND INFECTIOUS DISEASES (AID) PMP 2012 REPORT. , 2013, , .		0
137	Oncolytic virus therapies. Pharmaceutical Patent Analyst, 2012, 1, 621-627.	0.4	6
138	Assessment ofChlamydia trachomatisinfection among Eastern European and West African women immigrants in South Italy. Sexually Transmitted Infections, 2012, 88, 70.2-71.	0.8	4
139	Immunogenicity of HIV Virus-Like Particles in Rhesus Macaques by Intranasal Administration. Vaccine Journal, 2012, 19, 970-973.	3.2	17
140	Molecular epidemiology of human herpesvirus 8 variants in Kaposi's sarcoma from Iranian patients. Virus Research, 2012, 163, 644-649.	1.1	23
141	An overview of viral oncology in Italy - report from the Pavia meeting on solid tumors. Infectious Agents and Cancer, 2012, 7, 23.	1.2	1
142	HPV type distribution in invasive cervical cancers in Italy: pooled analysis of three large studies. Infectious Agents and Cancer, 2012, 7, 26.	1.2	19
143	Innate immunity and hepatitis C virus infection: a microarray's view. Infectious Agents and Cancer, 2012, 7, 7.	1.2	11
144	Characterization of the Human Papillomavirus (HPV) Integration Sites into Genital Cancers. Pathology and Oncology Research, 2012, 18, 803-808.	0.9	20

#	Article	IF	Citations
145	Immunogenomics approaches for vaccine evaluation. Journal of Immunotoxicology, 2012, 9, 236-240.	0.9	5
146	HIV p24 as Scaffold for Presenting Conformational HIV Env Antigens. PLoS ONE, 2012, 7, e43318.	1.1	6
147	The immune score as a new possible approach for the classification of cancer. Journal of Translational Medicine, 2012, 10, 1.	1.8	656
148	Quality of life, lifestyle behavior and employment experience: A comparison between young and midlife survivors of gynecology early stage cancers. Gynecologic Oncology, 2012, 124, 444-451.	0.6	64
149	Effects of adjuvants on IgG subclasses elicited by virus-like Particles. Journal of Translational Medicine, 2012, 10, 4.	1.8	66
150	Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensus PCR HPV-DNA, and In Situ Hybridization. Infectious Agents and Cancer, 2012, 7, 4.	1.2	103
151	Multiparametric Analyses of Human PBMCs Loaded Ex Vivo with a Candidate Idiotype Vaccine for HCV-Related Lymphoproliferative Disorders. PLoS ONE, 2012, 7, e44870.	1.1	4
152	AIDS AND INFECTIOUS DISEASES (AID) PMP 2011 REPORT. , 2012, , 515-519.		0
153	Molecular characterization analysis of the outer protein layer (VP7) from human rotavirus A genotype G1 isolate identified in Iran: implications for vaccine development. New Microbiologica, 2012, 35, 415-27.	0.1	9
154	New adjuvants in evolving vaccine strategies. Expert Opinion on Biological Therapy, 2011, 11, 827-832.	1.4	15
155	Plant-derived Vaccines: Technologies & Applications. , 2011, , .		1
156	High prevalence of human papillomavirus infection in Eastern European and West African women immigrants in South Italy. Apmis, 2011, 119, 701-709.	0.9	22
157	Immunogenomics and systems biology of vaccines. Immunological Reviews, 2011, 239, 197-208.	2.8	65
158	Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix. Gynecologic Oncology, 2011, 121, 32-42.	0.6	77
159	Translating Tumor Antigens into Cancer Vaccines. Vaccine Journal, 2011, 18, 23-34.	3.2	183
160	Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Review of Vaccines, 2011, 10, 1569-1583.	2.0	82
161	TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma in Italian patients. Infectious Agents and Cancer, 2011, 6, 13.	1.2	22
162	Systems biology applied to vaccine and immunotherapy development. BMC Systems Biology, 2011, 5, 146.	3.0	26

#	Article	IF	Citations
163	Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons?. Immunotherapy, 2011, 3, 1203-1222.	1.0	34
164	Can HIV p24 Be a Suitable Scaffold for Presenting Env Antigens?. Vaccine Journal, 2011, 18, 2003-2004.	3.2	4
165	MDM2 and CDKN1A gene polymorphisms and risk of Kaposiâ€™s sarcoma in African and Caucasian patients. Biomarkers, 2011, 16, 42-50.	0.9	30
166	Human herpesvirus type 8 variants circulating in Europe, Africa and North America in classic, endemic and epidemic Kaposi's sarcoma lesions during pre-AIDS and AIDS era. Virology, 2010, 398, 280-289.	1.1	56
167	Human papillomavirus infection in urine samples from male renal transplant patients. Journal of Medical Virology, 2010, 82, 1179-1185.	2.5	17
168	Conformational HIV-1 Envelope on particulate structures: a tool for chemokine coreceptor binding studies. Journal of Translational Medicine, 2010, 9, S1.	1.8	7
169	HIV/HPV coinfection: state-of-the-art. Retrovirology, 2010, 7, .	0.9	1
170	Cardiac Tamponade and Heart Failure Due to Myopericarditis as a Presentation of Infection with the Pandemic H1N1 2009 Influenza A Virus. Journal of Clinical Microbiology, 2010, 48, 2298-2300.	1.8	30
171	Prevalence of Human Papillomavirus Types in High-Grade Cervical Intraepithelial Neoplasia and Cancer in Italy. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2389-2400.	1.1	64
172	Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders. Journal of Translational Medicine, 2010, 8, 18.	1.8	12
173	PharmaPlant: the new frontier in vaccines. Expert Review of Vaccines, 2010, 9, 805-807.	2.0	17
174	Plant-based anti-HIV-1 strategies: vaccine molecules and antiviral approaches. Expert Review of Vaccines, 2010, 9, 925-936.	2.0	15
175	Virus-Like Particles as Particulate Vaccines. Current HIV Research, 2010, 8, 299-309.	0.2	57
176	Infectious agents and human malignancies. Frontiers in Bioscience - Landmark, 2009, Volume, 3455.	3.0	19
177	Th2 Polarization in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus (HIV)-Infected Subjects, as Activated by HIV Virus-Like Particles. Journal of Virology, 2009, 83, 304-313.	1.5	32
178	<i>TP53</i> Codon 72 Polymorphism in Classic, Endemic and Epidemic Kaposiâ€™s Sarcoma in African and Caucasian Patients. Oncology, 2009, 77, 328-334.	0.9	11
179	Molecular immune signatures of HIVâ€‘1 vaccines in human PBMCs. FEBS Letters, 2009, 583, 3004-3008.	1.3	23
180	High-level expression of the HIV-1 Pr55gag polyprotein in transgenic tobacco chloroplasts. Planta, 2009, 229, 1109-1122.	1.6	95

#	Article	IF	Citations
181	Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infectious Agents and Cancer, 2009, 4, 8.	1.2	393
182	Detection of mucosal and cutaneous human papillomaviruses in oesophagitis, squamous cell carcinoma and adenocarcinoma of the oesophagus. Journal of Clinical Virology, 2009, 45, 28-33.	1.6	44
183	Virus-like particle vaccines and adjuvants: the HPV paradigm. Expert Review of Vaccines, 2009, 8, 1379-1398.	2.0	32
184	Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma. Journal of Translational Medicine, 2009, 7, 85.	1.8	31
185	Unsung Hero Robert C. Gallo. Science, 2009, 323, 206-207.	6.0	2
186	Incidence of breast cancer in Italy: mastectomies and quadrantectomies performed between 2000 and 2005. Journal of Experimental and Clinical Cancer Research, 2009, 28, 86.	3.5	21
187	Short Communication: Limited Induction of IL-10 in PBMCs from HIV-Infected Subjects Treated with HIV-VLPs. AIDS Research and Human Retroviruses, 2009, 25, 819-822.	0.5	7
188	AIDS AND INFECTIOUS DISEASES PMP. , 2009, , .		0
189	Translational fusion of chloroplast-expressed human papillomavirus type 16 L1 capsid protein enhances antigen accumulation in transplastomic tobacco. Transgenic Research, 2008, 17, 1091-1102.	1.3	78
190	A pilot study on the distribution of human papillomavirus genotypes and HPVâ€16 variants in cervical neoplastic lesions from Ecuadorian women. Journal of Medical Virology, 2008, 80, 1959-1965.	2.5	15
191	Human papillomavirus genotypes and HPV16 variants in penile carcinoma. International Journal of Cancer, 2008, 122, 132-137.	2.3	50
192	Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation. BMC Bioinformatics, 2008, 9, S5.	1.2	30
193	Molecular and phylogenetic analysis of HIV-1 variants circulating in Italy. Infectious Agents and Cancer, 2008, 3, 13.	1.2	9
194	Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infectious Agents and Cancer, 2008, 3, 14.	1.2	24
195	Analysis of TP53 codon 72 polymorphism in HPV-positive and HPV-negative penile carcinoma. Cancer Letters, 2008, 269, 159-164.	3.2	15
196	Human papillomavirus (HPV) genotypes and HPV16 variants in human immunodeficiency virus-positive Italian women. Journal of General Virology, 2008, 89, 1380-1389.	1.3	40
197	INTRODUCING INFECTIOUS AGENTS AND CANCER SESSION. , 2008, , .		0
198	HIV Type 1 Subtype A Epidemic in Injecting Drug User (IDU) Communities in Iran. AIDS Research and Human Retroviruses, 2007, 23, 1569-1574.	0.5	18

#	Article	IF	Citations
199	Genetic and phylogenetic evolution of HIV-1 in a low subtype heterogeneity epidemic: the Italian example. Retrovirology, 2007, 4, 34.	0.9	10
200	Prevalence of human papillomavirus genotypes and their variants in high risk West Africa women immigrants in South Italy. Infectious Agents and Cancer, 2007, 2, 1.	1.2	39
201	Evolution of the HIV-1 V3 region in the Italian epidemic. New Microbiologica, 2007, 30, 1-11.	0.1	6
202	Introducing Infectious Agents and Cancer. Infectious Agents and Cancer, 2006, 1, 1.	1.2	3
203	Prevalence of alpha-papillomavirus genotypes in cervical squamous intraepithelial lesions and invasive cervical carcinoma in the Italian population. Journal of Medical Virology, 2006, 78, 1663-1672.	2.5	49
204	Baculovirus-Derived Human Immunodeficiency Virus Type 1 Virus-Like Particles Activate Dendritic Cells and Induce Ex Vivo T-Cell Responses. Journal of Virology, 2006, 80, 9134-9143.	1.5	111
205	Evaluating the role of human papillomaviruses in conjunctival neoplasia. British Journal of Cancer, 2006, 94, 446-449.	2.9	41
206	TP53 codon 72 polymorphism and risk of conjunctival squamous cell carcinoma in Uganda. Cancer Detection and Prevention, 2005, 29, 501-508.	2.1	19
207	Evaluation of a modified version of Heteroduplex Mobility Assay for rapid screening of HIV-1 isolates in epidemics characterized by mono/dual clade predominance. Journal of Virological Methods, 2005, 124, 123-134.	1.0	5
208	Induction of Systemic and Mucosal Cross-Clade Neutralizing Antibodies in BALB/c Mice Immunized with Human Immunodeficiency Virus Type 1 Clade A Virus-Like Particles Administered by Different Routes of Inoculation. Journal of Virology, 2005, 79, 7059-7067.	1.5	73
209	Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation. Journal of Translational Medicine, 2005, 3, 45.	1.8	41
210	Analysis of human papillomavirus type-16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer. Journal of Medical Virology, 2004, 74, 117-126.	2.5	70
211	Screening of HIV-1 Isolates by Reverse Heteroduplex Mobility Assay and Identification of Non-B Subtypes in Italy. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, 1295-1306.	0.9	24
212	SYSTEMIC AND MUCOSAL IMMUNE RESPONSES INDUCED BY HIV-1 DNA AND HIV-PEPTIDE OR VLP BOOSTER IMMUNIZATION. , 2004, , .		0
213	Kaposi's sarcoma: aetiopathogenesis, histology and clinical features. Journal of the European Academy of Dermatology and Venereology, 2003, 17, 138-154.	1.3	65
214	Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. Antiviral Research, 2002, 54, 189-201.	1.9	68
215	High efficient production of Pr55gag virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Research, 2001, 49, 35-47.	1.9	80
216	The Uganda study on HPV variants and genital cancers. Journal of Clinical Virology, 2000, 19, 31-41.	1.6	37

#	Article	IF	Citations
217	Identification and functional analysis of sequence rearrangements in the long control region of human papillomavirus type 16 Af-1 variants isolated from Ugandan penile carcinomas. Journal of General Virology, 2000, 81, 2969-2982.	1.3	32
218	Sequence Note: A Novel Glycoprotein 120 Sequence from an HIV Type 1 Isolate of the A Clade Identified in North Uganda. AIDS Research and Human Retroviruses, 1998, 14, 1287-1289.	0.5	17
219	Herpesvirus-like DNA sequences detected in endemic, classic, iatrogenic and epidemic Kaposi's sarcoma (KS) biopsies. International Journal of Cancer, 1996, 65, 25-28.	2.3	122
220	Heteroduplex mobility assay and phylogenetic analysis of V3 region sequences of human immunodeficiency virus type 1 isolates from Gulu, northern Uganda. The Italian-Ugandan Cooperation AIDS Program. Journal of Virology, 1995, 69, 7971-7981.	1.5	55
221	Analysis of HIV-1 env gene V3 loop sequence in a southern Italian cohort of intravenous drug users. Aids, 1994, 8, 268.	1.0	9
222	The human immunodeficiency virus type 1 Tat protein transactivates tumor necrosis factor beta gene expression through a TAR-like structure. Journal of Virology, 1994, 68, 2677-2682.	1.5	111
223	Human Immunodeficiency Virus Type 1 <i>tat</i> Gene Enhances Human Papillomavirus Early Gene Expression. Intervirology, 1993, 36, 57-64.	1.2	68
224	Human papillomavirus (hpv) DNA in penile carcinomas and in two cell lines from high-incidence areas for genital cancers in Africa. International Journal of Cancer, 1992, 51, 587-592.	2.3	24
225	HIV and Herpesviruses in Immunodeficiency and Cancers. , 1988, , 260-271.		0
226	Plasmid mediated mutagenesis of a cellular gene in transfected eukaryotic cells. Nucleic Acids Research, 1987, 15, 561-573.	6.5	25
227	Characterization of the integration site of the CMV mtr in a tumor cell line. Virology, 1987, 156, 74-83.	1.1	6
228	Multifractionation of 60Co gamma-rays reduces neoplastic transformation in vitro. Carcinogenesis, 1984, 5, 193-197.	1.3	37
229	RECOVERY FROM INHIBITION BY UV-IRRADIATION OF ORNITHINE DECARBOXYLASE INDUCTION IN HUMAN CELLS: IMPLICATION OF EXCISION REPAIR. Photochemistry and Photobiology, 1982, 35, 671-674.	1.3	2
230	Fission-spectrum neutrons at reduced dose rates enhance neoplastic transformation. Nature, 1982, 298, 67-69.	13.7	164